Form 4: Mainz Biomed CEO Reports Stock Transaction
Insider Transaction (Form 4)
David E. Lazar, Chief Executive Officer, a Director and 10% owner of Mainz Biomed N.V., reported multiple transactions in common stock on August 5, 2026.
Summary
- Conversion of derivative: acquired 9,000,000 Ordinary Shares at $9.00 ($81,000,000) on August 5, 2026; holds 9,000,000 after (Direct).
- Conversion of derivative: acquired 9,000,000 Ordinary Shares at $9.00 ($81,000,000) on August 5, 2026; holds 18,000,000 after (Direct).
- Conversion of derivative: acquired 9,000,000 Ordinary Shares at $9.00 ($81,000,000) on August 5, 2026; holds 27,000,000 after (Direct).
- Conversion of derivative: acquired 28,057,500 Ordinary Shares at $225.00 ($6,312,937,500) on August 5, 2026; holds 55,057,500 after (Direct).
- Conversion of derivative: disposed of 1,000,000 Series A Preferred Shares on August 5, 2026 (Direct).
- Conversion of derivative: disposed of 1,000,000 Series B Preferred Shares on August 5, 2026 (Direct).
- Conversion of derivative: disposed of 1,000,000 Series C Preferred Shares on August 5, 2026 (Direct).
- Conversion of derivative: disposed of 124,700 Series D Preferred Shares on August 5, 2026; holds 875,300 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David E. Lazar — Director, Officer (Chief Executive Officer), 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-05 | Conversion of derivative | Ordinary Shares | 9,000,000 | $9 | $81.0M | 9,000,000 |
| 2026-08-05 | Conversion of derivative | Ordinary Shares | 9,000,000 | $9 | $81.0M | 18,000,000 |
| 2026-08-05 | Conversion of derivative | Ordinary Shares | 9,000,000 | $9 | $81.0M | 27,000,000 |
| 2026-08-05 | Conversion of derivative | Ordinary Shares | 28,057,500 | $225 | $6.3B | 55,057,500 |
| 2026-08-05 | Conversion of derivative | Series A Preferred Shares | 1,000,000 | — | — | 0 |
| 2026-08-05 | Conversion of derivative | Series B Preferred Shares | 1,000,000 | — | — | 0 |
| 2026-08-05 | Conversion of derivative | Series C Preferred Shares | 1,000,000 | — | — | 0 |
| 2026-08-05 | Conversion of derivative | Series D Preferred Shares | 124,700 | — | — | 875,300 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-05 | Conversion of derivative (9,000,000 shares) |
| 2026-08-05 | Conversion of derivative (9,000,000 shares) |
| 2026-08-05 | Conversion of derivative (9,000,000 shares) |
| 2026-08-05 | Conversion of derivative (28,057,500 shares) |
| 2026-08-05 | Conversion of derivative (1,000,000 shares) |
| 2026-08-05 | Conversion of derivative (1,000,000 shares) |
| 2026-08-05 | Conversion of derivative (1,000,000 shares) |
| 2026-08-05 | Conversion of derivative (124,700 shares) |
Keywords
insider transaction, Form 4, QUCY, Quantum Cyber N.V., neutral, David E. Lazar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.